PDF(Pubmed)
Abstract：
BACKGROUND: While many studies on the determinants of post-COVID-19 conditions (PCC) have been conducted, little is known about the relationship between SARS-CoV-2 variants and PCC. This study aimed to assess the association between different SARS-CoV-2 variants and the probability of having PCC three months after the infection.
METHODS: This study was a longitudinal cohort study conducted between April 2021 and September 2022 in Belgium. In total, 8,238 adults with a confirmed SARS-CoV-2 infection were followed up between the time of their infection and three months later. The primary outcomes were the PCC status three months post infection and seven PCC symptoms categories (neurocognitive, autonomic, gastrointestinal, respiratory, musculoskeletal, anosmia and/or dysgeusia, and other manifestations). The main exposure variable was the type of SARS-CoV-2 variants (i.e. Alpha, Delta, and Omicron), extracted from national surveillance data. The association between the different SARS-CoV-2 variants and PCC as well as PCC symptoms categories was assessed using multivariable logistic regression.
RESULTS: The proportion of PCC among participants infected during the Alpha, Delta, and Omicron-dominant periods was significantly different and respectively 50%, 50%, and 37%. Participants infected during the Alpha- and Delta-dominant periods had a significantly higher odds of having PCC than those infected during the Omicron-dominant period (OR = 1.61, 95% confidence interval [CI] = 1.33-1.96 and OR = 1.73, 95%CI = 1.54-1.93, respectively). Participants infected during the Alpha and Delta-dominant periods were more likely to report neurocognitive, respiratory, and anosmia/dysgeusia symptoms of PCC.
CONCLUSIONS: People infected during the Alpha- and Delta-dominant periods had a higher probability of having PCC three months after infection than those infected during the Omicron-dominant period. The lower probability of PCC with the Omicron variant must also be interpreted in absolute figures. Indeed, the number of infections with the Omicron variant being higher than with the Alpha and Delta variants, it is possible that the overall prevalence of PCC in the population increases, even if the probability of having a PCC decreases.
METHODS: This study was a longitudinal cohort study conducted between April 2021 and September 2022 in Belgium. In total, 8,238 adults with a confirmed SARS-CoV-2 infection were followed up between the time of their infection and three months later. The primary outcomes were the PCC status three months post infection and seven PCC symptoms categories (neurocognitive, autonomic, gastrointestinal, respiratory, musculoskeletal, anosmia and/or dysgeusia, and other manifestations). The main exposure variable was the type of SARS-CoV-2 variants (i.e. Alpha, Delta, and Omicron), extracted from national surveillance data. The association between the different SARS-CoV-2 variants and PCC as well as PCC symptoms categories was assessed using multivariable logistic regression.
RESULTS: The proportion of PCC among participants infected during the Alpha, Delta, and Omicron-dominant periods was significantly different and respectively 50%, 50%, and 37%. Participants infected during the Alpha- and Delta-dominant periods had a significantly higher odds of having PCC than those infected during the Omicron-dominant period (OR = 1.61, 95% confidence interval [CI] = 1.33-1.96 and OR = 1.73, 95%CI = 1.54-1.93, respectively). Participants infected during the Alpha and Delta-dominant periods were more likely to report neurocognitive, respiratory, and anosmia/dysgeusia symptoms of PCC.
CONCLUSIONS: People infected during the Alpha- and Delta-dominant periods had a higher probability of having PCC three months after infection than those infected during the Omicron-dominant period. The lower probability of PCC with the Omicron variant must also be interpreted in absolute figures. Indeed, the number of infections with the Omicron variant being higher than with the Alpha and Delta variants, it is possible that the overall prevalence of PCC in the population increases, even if the probability of having a PCC decreases.
摘要：
背景：虽然已经对COVID-19后条件（PCC）的决定因素进行了许多研究，关于SARS-CoV-2变体与PCC之间的关系知之甚少。这项研究旨在评估不同SARS-CoV-2变体与感染后三个月发生PCC的可能性之间的关联。
方法：本研究是一项纵向队列研究，于2021年4月至2022年9月在比利时进行。总的来说,在感染时间和三个月后，对8,238名确诊为SARS-CoV-2感染的成年人进行了随访。主要结果是感染后三个月的PCC状态和七个PCC症状类别(神经认知，自主性,胃肠,呼吸,肌肉骨骼，失语症和/或味觉障碍，和其他表现)。主要暴露变量是SARS-CoV-2变体的类型（即Alpha，Delta,和Omicron），从国家监测数据中提取。使用多变量逻辑回归评估不同SARS-CoV-2变体与PCC以及PCC症状类别之间的关联。
结果：在Alpha期间感染的参与者中PCC的比例，Delta,和Omicron-显性周期显著不同，分别为50%，50%,和37%。在Alpha和Delta优势期感染的参与者患PCC的几率明显高于在Omicron优势期感染的参与者（OR=1.61，95％置信区间[CI]=1.33-1.96和OR=1.73，95CI=1.54-1.93，分别）。在Alpha和Delta主导期感染的参与者更有可能报告神经认知，呼吸,和PCC的嗅觉缺失/味觉障碍症状。
结论：在Alpha和Delta优势期感染的人在感染后三个月患PCC的概率高于在Omicron优势期感染的人。具有Omicron变体的PCC的较低概率也必须用绝对数字来解释。的确,Omicron变体的感染数量高于Alpha和Delta变体，PCC在人群中的总体患病率可能会增加，即使有PCC的概率降低。
方法：本研究是一项纵向队列研究，于2021年4月至2022年9月在比利时进行。总的来说,在感染时间和三个月后，对8,238名确诊为SARS-CoV-2感染的成年人进行了随访。主要结果是感染后三个月的PCC状态和七个PCC症状类别(神经认知，自主性,胃肠,呼吸,肌肉骨骼，失语症和/或味觉障碍，和其他表现)。主要暴露变量是SARS-CoV-2变体的类型（即Alpha，Delta,和Omicron），从国家监测数据中提取。使用多变量逻辑回归评估不同SARS-CoV-2变体与PCC以及PCC症状类别之间的关联。
结果：在Alpha期间感染的参与者中PCC的比例，Delta,和Omicron-显性周期显著不同，分别为50%，50%,和37%。在Alpha和Delta优势期感染的参与者患PCC的几率明显高于在Omicron优势期感染的参与者（OR=1.61，95％置信区间[CI]=1.33-1.96和OR=1.73，95CI=1.54-1.93，分别）。在Alpha和Delta主导期感染的参与者更有可能报告神经认知，呼吸,和PCC的嗅觉缺失/味觉障碍症状。
结论：在Alpha和Delta优势期感染的人在感染后三个月患PCC的概率高于在Omicron优势期感染的人。具有Omicron变体的PCC的较低概率也必须用绝对数字来解释。的确,Omicron变体的感染数量高于Alpha和Delta变体，PCC在人群中的总体患病率可能会增加，即使有PCC的概率降低。
